Asthma during pregnancy Review article
Article Sidebar
Main Article Content
Abstract
Medicines used in asthma are safe for the pregnant woman and the fetus, yet almost 40% of pregnant patients discontinue treatment due to concerns about the condition of the fetus. Discontinuation of therapy is associated with an increased risk of asthma exacerbations, worsening of the patient's condition and poses a threat to her child. For this reason, GINA has recommended for many years, treatment should be continued unchanged during pregnancy, as long as asthma was controlled by the current treatment. The most effective drugs with the lowest bioavailability are recommended, as well as combined preparations. The benefits of inhaled GCS ± LABA therapy to maintain asthma control and prevent exacerbations even outweigh the potential risk of routinely administered asthma medications. The development of severe asthma exacerbations requiring the use of oral steroids may be associated with the risk of preterm labor and low birth weight.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Global Strategy for Asthma Management and Prevention
(2021 update) (access: 10.03.2022).
3. Przybyłowski T. Choroby internistyczne u kobiet w ciąży. Medycyna po Dyplomie 2012; 9.
4. Sarnecki J. Spożycie wielonienasyconych kwasów tłuszczowych w ciąży a ryzyko astmy u dziecka. Standardy Medyczne.
5. Murphy VE. Managing asthma in pregnancy. Breathe (Sheff). 2015; 11(4): 258-67. http://doi.org/10.1183/20734735.007915.
6. Popa M, Peltecu G, Gica N et al. Asthma in Pregnancy. Review of Current Literature and Recommendations. Maedica (Bucur). 2021; 16(1): 80-87. http://doi.org/10.26574/maedica.2020.16.1.80.
7. Cossette B, Beauchesne MF, Forget A et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol. 2014; 112: 459.
8. Charlton RA, Snowball JM, Nightingale AL et al. Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study. J Allergy Clin Immunol Pract. 2015; 3: 772.
9. Charakterystyka produktu leczniczego Fluticomb SmPC section 4.6. Wpływ na płodność, ciążę i laktację (access: 10.03.2022).
10. National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. Managing asthma during pregnancy: recommendations for pharmacologic treatment – 2004 update. J Allergy Clin Immunol. 2005; 115: 34-46.